Vir Biotechnology Inc
Research Vir Biotechnology Inc (VIR) on Bullrun: market cap USD 1.81B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVIR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.81B
- Financial periodQ2 2026
- RevenueUSD 238.94M
- Net incomeUSD 80.08M
- Free cash flowUSD 123.29M
- Gross margin100.0%
Valuation Snapshot
latest market cap is USD 1.81B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 68.56M | -USD 437.99M | -USD 396.61M | 100.0% | -3.16 | USD 232.19M | USD 97.85M | USD 765.28M |
| FY2024 | USD 74.21M | -USD 521.96M | -USD 453.65M | 98.9% | -3.83 | USD 222.95M | USD 97.89M | USD 1.15B |
| FY2023 | USD 86.18M | -USD 615.12M | -USD 800.36M | 96.8% | -4.59 | USD 241.58M | USD 124.54M | USD 1.59B |
| FY2022 | USD 1.62B | USD 515.84M | USD 1.60B | 90.9% | 3.83 | USD 848.63M | USD 134.31M | USD 2.08B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.81B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 841.03M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.01B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.35B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 3.37B | 3.0 | n/a | n/a |
| 2021 | 2021-12-31 | USD 5.49B | 10.8 | n/a | n/a |
About Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Vir Biotechnology Inc's market cap?
Vir Biotechnology Inc's market capitalization is USD 1.81B.
What does Vir Biotechnology Inc do?
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors.